Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Imugene ( (AU:IMU) ).
Imugene Limited announced a webinar to discuss positive feedback from the FDA regarding their azer-cel program, highlighting its potential to advance into pivotal studies. This development underscores the program’s clinical and commercial promise, potentially strengthening Imugene’s position in the immuno-oncology market.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene is a clinical-stage immuno-oncology company focused on developing innovative immunotherapies that activate the immune system to combat cancer. Their pipeline includes a CAR T cell therapy targeting CD19 for blood cancers and an oncolytic virotherapy for various cancers, supported by a team of international cancer experts.
YTD Price Performance: -74.56%
Average Trading Volume: 2,270,181
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$100.9M
For detailed information about IMU stock, go to TipRanks’ Stock Analysis page.